Stock DCPH DECIPHERA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Market Closed - Nasdaq
Other stock markets
 04:00:01 2024-05-31 pm EDT 		5-day change 1st Jan Change
25.54 USD +0.04% Intraday chart for Deciphera Pharmaceuticals, Inc. +0.12% +58.34%
May. 10 Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 North American Morning Briefing : Traders Wait for -2- DJ

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
BU
INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH
PR
Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.
PR
DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders
BU
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
BU
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
PR
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BU
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
BU
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
BU
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
BU
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
BU
GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe
AQ
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
BU
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
BU
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
BU
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
AQ
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DCPH Stock
  4. News Deciphera Pharmaceuticals, Inc.
  5. Press Releases